Screening for early detection of oral cancer and related disorders
Official title: Screening for Oral Cancer for Early Detection of Premalignant Disorders
Run by Dalarna County Council, Sweden · NCT05296941 · Data updated 2026-11-12
This study is testing a new, easy way to check for early signs of oral cancer in high-risk people, like tobacco and heavy alcohol users, to help catch it sooner and improve survival rates.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Dalarna County Council, Sweden Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Falun, Dalarna County) |
| Status | Recruiting |
| Started | August 1, 2023 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2029 |
| Registry record updated | September 8, 2023 |
| Trial ID | NCT05296941 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals aged 18 and older with a clinical diagnosis of leukoplakia, erythroplakia, or proliferative verrucous leukoplakia.
✕Probably not a fit
Patients currently undergoing chemotherapy or radiotherapy, or those unable to understand information in Swedish, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to develop a cost-effective system for the continuous monitoring of mucosal lesions in the oral cavity using non-invasive brush biopsy techniques. By focusing on high-risk individuals, such as tobacco users and those with excessive alcohol consumption, the study seeks to implement early diagnostic screening to improve survival rates for oral cancer. The approach is designed to be manageable within primary dental care settings, potentially reducing the reliance on more invasive tissue biopsies. The ultimate goal is to decrease the incidence of late-stage oral cancers, which have significantly poorer prognoses.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection of oral cancers, improving survival rates and quality of life for patients.
How similar studies have gone: Other studies have shown promise in using non-invasive techniques for early cancer detection, suggesting that this approach could be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: • Persons 18 years of age or older who have the clinical diagnosis of leukoplakia, erythroplakia or proliferative verrukös leukoplakia Exclusion Criteria: * People who cannot read and understand information in Swedish. * Ongoing chemotherapy and/or radiotherapy.
Where it's running
-
Kristina Edman
Falun, Dalarna County, Sweden Recruiting
Study contacts
- Principal investigator: Public dental care — Uppsala University
- Study coordinator: Kristina Edman, PhD
- Email: kristina.edman@regiondalarna.se
- Phone: +46(0)70 5349476
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tissue adhesive vs sutures for closing oral biopsy wounds
This study tests whether a tissue adhesive called PeriAcryl 90 HV can close oral biopsy sites as effectively as traditional sutures in people with oral fibromas.
-
Dezocine versus nalbuphine with sufentanil for pain control after oral cancer surgery with free-flap reconstruction
This will see if adding dezocine or nalbuphine to sufentanil reduces pain and complications for adults undergoing oral cancer surgery with free-flap reconstruction.
-
Comparing two surgical approaches for early mouth cancers
This study is testing whether a less invasive surgery for early mouth cancers can provide similar survival rates while being easier on patients and more affordable than the standard approach.
-
Chemotherapy for advanced oral cancer patients with high cyclin D1 expression
This study is testing if a specific chemotherapy treatment can help people with advanced oral cancer who have high levels of a protein called cyclin D1 live longer and stay cancer-free after treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.